

AD_____

Award Number: W81XWH-07-1-0052

TITLE: Exploring the Mechanisms of Pathogenesis in Prostate Cancer Involving
TMPRSS2-ERG (Or ETV1) Gene Rearrangement

PRINCIPAL INVESTIGATOR: Stuart H. Orkin, M.D.

CONTRACTING ORGANIZATION: Children's Hospital
Boston, MA 02115

REPORT DATE: January 2009

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-01-2009		2. REPORT TYPE Final		3. DATES COVERED (From - To) 15 DEC 2006 - 14 DEC 2008	
4. TITLE AND SUBTITLE Exploring the Mechanisms of Pathogenesis in Prostate Cancer Involving TMPRSS2-ERG (Or ETV1) Gene Rearrangement				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0052	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Stuart H. Orkin, M.D. E-Mail: stuart_orkin@dfci.harvard.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Children's Hospital Boston, MA 02115				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Recently, gene rearrangements involving ETS family transcription factors have been identified in >50% of prostate cancer cases. To address roles of these ETS factors, especially ERG, the most frequently rearranged ETS gene in prostate cancer, as well as in normal prostate development, we planned to, 1. Generate conditional knockin mouse models of prostate cancer based on the newly identified TMPRSS2-ERG (or ETV1) gene arrangements; 2 Explore roles of Erg during development as well as in normal prostate by disrupting its expression in mouse; 3. Identify downstream target genes of ERG or ETV1 in human prostate cancer cell lines carrying these gene arrangements using the ChIP-on-Chip approach. During the first year of this award, we have made significant progress in establishing systems and reagents for all three aims mentioned above. Specifically, we have successfully created conditional knockin mice expressing truncated human ERG and ETV1 (as found in patients) from the endogenous mouse Tmprss2 locus. We have generated an Erg knockdown allele in mice, which would allow us to study its roles during both embryonic development and postnatal prostate development. We have also made biotinylated ERG and ETV1 in prostate cell lines, which would allow us to identify the downstream targets of these factors in prostate epithelial cells. Further studies using these animal and cell culture models would allow us to develop preclinical animal models, and to identify and validate novel therapeutic targets, for treating prostate cancer.					
15. SUBJECT TERMS Prostate cancer, gene targeting, mouse model, gene rearrangement, oncogenesis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	7
References.....	8
Appendices.....	8
Supporting Data.....	9

Introduction:

Prostate cancer is among the most frequently diagnosed cancers and the second most common cause of male cancer-related death (1, 2). It arises through a progression from an initial benign stage to frank malignancy, most often correlating with androgen-dependence and then androgen-independence in the late stage (3). Among genetic changes accompanying prostate cancer, of greatest interest are genetic “hits” in prostate epithelial cells that might represent initiating events for oncogenesis or consistent somatic mutations that specifically affect these cells. Identification of and modeling these causal genetic alterations would be invaluable in providing novel therapeutic targets and prognostic markers. Recently, chromosomal rearrangements between androgen-responsive genes, such as *TMPRSS2*, and genes encoding the ETS family transcription factors (*ERG*, *ETV1*, *ETV4*, and *ETV5*) were identified in >50% of prostate cancer cases (4-14). Due to their high incidence in prostate cancer, these may represent the most common gene rearrangements identified in human cancers. In addition, in analogy to the role of translocations in hematological malignancies, these chromosomal rearrangements represent either the initiating event in oncogenesis or a critical and consistent set in the cancer progression. Among ETS genes involved in these rearrangements, the most common one is *ERG*, followed by *ETV1* (15). Arrangements of coding regions of these ETS genes to control regions of androgen-responsive genes presumably lead to overexpression of these proto-oncogenes. In this study, we plan to create and characterize a series of mouse models based on *TMPRSS2-ERG* (or *ETV1*) gene rearrangements to study roles of these ETS genes, especially *ERG*, in development and in prostate tumorigenesis. We also plan to use biochemical approaches to identify downstream targets of *ERG* as well as its interaction partners. These studies would allow us to develop preclinical animal models, and to identify and validate novel therapeutic targets, for treating prostate cancer.

Body:

Specific aim 1: Establish a novel Cre/lox conditional knockin mouse model of prostate cancer based on the newly identified TMPRSS2-ERG(or ETV1) gene arrangements.

We proposed to use the Cre/lox conditional approach to model prostate cancer based on the *TMPRSS2-ERG/ETV1* chromosomal rearrangements. We planned to use two different strategies to achieve this aim. In one strategy, we proposed to generate conditional knockin alleles to express the N-terminal truncated human *ERG* (or *ETV1*, as found in patients) from the mouse endogenous *Tmprss2* locus. In a second strategy, we proposed to create knockin alleles of both *Tmprss2* and *Erg* by introducing a single loxP site to each allele, which would then permit Cre-mediated interchromosomal recombination as well as intrachromosomal excision.

For the first strategy, we knocked in the N-terminus-truncated human *ERG* or *ETV1* cDNA together with an ires-Gfp marker into the exon 2 of mouse *Tmprss2* locus. We placed a transcriptional stopper cassette together with Neo (*Neo-ST*) upstream of the knockin cDNA. The *Neo-ST* cassette is flanked by loxP sites. Cre-mediated excision would remove this cassette and activate the *Tmprss2-ERG* or *ETV1* fusion genes. Several correctly targeted independent ES clones from either *ERG* or *ETV1* knockins (*Tmprss2-Neo-ST-ERG/ETV1*) were injected into mouse blastocysts and a colony of germline-transmitted heterozygous and homozygous knockin mice was established. These knockin mice have been bred to the prostate-specific *PB-Cre4* transgenic mouse (16) to generate *PB-Cre4;Tmprss2-Neo-ST-ERG/ETV1* double transgenic males. In addition, we also generated several stopper-removed knockin *Tmprss2-ERG* ES cell lines *in vitro* and made chimeric male mice from them by blastocysts injection. From these male chimeras, we have also established a colony of stopper-removed knockin *Tmprss2-ERG* heterozygous (one copy of *Tmprss2-ERG*) and homozygous (two copies of *Tmprss2-ERG*) mice. In these animals, since the *Neo-ST* cassette has already been removed, *ERG* expression is activated and under the control of the *Tmprss2* promoter. In fact, by RT-PCR, we confirmed that the *Tmprss2-ERG* fusion transcript was expressed from the endogenous *Tmprss2* locus from prostate tissues of the *Tmprss2-ERG* chimeric males (Figure 1), suggesting the human *ERG* cDNA was indeed correctly targeted to the mouse *Tmprss2* locus.

We have followed the *Tmprss2-ERG* heterozygous and homozygous males for up to eight months and have not observed any abnormality in their prostates, suggesting ectopic expression of *ERG* alone in prostate is not sufficient to initiate prostate tumorigenesis and additional mutation(s) may be needed to cooperate with *ERG* for the development of prostate cancer. Recently, several groups reported prostate intraepithelial neoplasia (PIN) lesions in prostates from transgenic male mice overexpressing *ERG* from the probasin promoter (*PB-ERG*), although the reported phenotype is very weak and apparently *ERG* overexpression alone is not

sufficient to drive prostate cancer development (17, 18). Genetically, the major difference between our knockin model and the reported transgenic models is that in our model, similar to what occurs in human patients, one or both copies of the endogenous *Tmprss2* gene is disrupted, whereas in *PB-ERG* transgenic mice, both alleles of *Tmprss2* are not affected. TMPRSS2 is an androgen regulated transmembrane serine protease that belongs to the type II transmembrane protease (TTSP) family (19). It is overexpressed in both prostatic hyperplasia and prostate cancers (20, 21). It is also mislocalized (cytoplasm compared to its normal location in the cell membrane) in most high-grade prostate tumors (20). These suggest that TMPRSS2 may also play a role in prostate tumorigenesis. If this is the case, overexpression of *ERG* and disruption of *Tmprss2* may have opposite effects on prostate tumorigenesis and they may cancel each other in our knockin model. Thus, future study may need to focus on assessing the role of *Tmprss2* on prostate tumorigenesis as well.

For the second strategy, we aimed to introduce a single loxP site to both the *Tmprss2* and the *Erg* loci, respectively. If the two knockin loxP sites are located on the same chromosome (chromosome 16 for mice), Cre-mediated recombination would delete the ~3Mb region between them, and generate the *Tmprss2-Erg* fusion gene following deletion. If the two loxP sites are knocked into two different chromosome 16s, then Cre-mediated recombination would lead to chromosomal translocation. The *Tmprss2-Erg* fusion gene would be created following translocation. To generate such a model, we first introduced the above-described floxed *Neo-ST* cassette into the *Erg* locus in the intron upstream of its exon 4. This immediately gave us a knockdown allele for *Erg*, which would allow us to study the role of *Erg* in normal development (will discuss in the progress for specific aim 2). In ES cells carrying this *Erg* knockdown (kd) allele, we expressed Cre transiently *in vitro* to remove the floxed *Neo-ST* cassette. After excision, only a single loxP site remains. We then performed sequential targeting from these ES cells to introduce the second loxP site into the *Tmprss2* locus. This was also achieved through the introduction of the floxed *Neo-ST* cassette. We initially planned to remove the *Neo-ST* cassette by Cre-mediated recombination so that only one loxP site would remain in the *Tmprss2* locus. However, transient transfection of sequentially targeted ES cells by Cre efficiently excised both the *Neo-ST* cassette and the 3Mb region between *Erg* and *Tmprss2*. The correct *Tmprss2-Erg* recombination was confirmed by PCR and sequencing (Figure 2). This PCR strategy also allowed us to determine whether two targeting events occurred on the same chromosome 16, or two different 16s in sequentially targeted ES clones. Overall, we obtained two ES clones with loxP sites on the same chromosome 16 and one ES clone targeted to two different chromosome 16s. We have generated germline-transmitted mice from these ES clones and are crossing them with *PB-Cre4* mice to achieve prostate-specific recombination between the *Erg* and *Tmprss2* loci. *TMPRSS2-ERG* fusion with interstitial deletion is the most common gene fusion subtype identified in prostate cancer patients and more importantly, a recent study found in metastatic prostate tumors, if they carry the *TMPRSS2-ERG* fusion, it is always the subtype with deletion (22). This suggests haploinsufficiency of gene(s) deleted between *TMPRSS2* and *ERG* may play a role in promoting metastasis. The mice (*PB-Cre4;Tmprss2-loxP-3Mb-loxP-Erg*) we generated with prostate-specific excision of the equivalent region between *Tmprss2* and *Erg* on mouse chromosome 16 would allow us to study this (Figure 2).

Since overexpression of *ERG* alone is not sufficient to initiate prostate cancer development, we also started to test a potential synergy between *Tmprss2-ERG* or *ETV1* fusion models and other mouse models of prostate cancer. We acquired *Pten* conditional knockout mice (23) and have started to breed this strain to our *Tmprss2-ERG* knockin mice. Both the *Pten* conditional allele and the *Tmprss2-ERG* conditional allele would be activated by breeding in the prostate-specific *PB-Cre4* transgene. This ongoing experiment would eventually allow us to test if *ERG* can cooperate with *Pten* deficiency for driving prostate cancer development.

In summary, in this specific aim, we have created knockin mouse models to model gene fusions found in >50% of human prostate cancer cases as we initially designed. Initial characterization of one of these models (*ERG* cDNA knockin model) suggests ectopic expression of *ERG* in prostate alone is not sufficient to initiate prostate tumorigenesis, additional mutation(s) (e.g., *Pten* loss) may be needed to cooperate with *ERG*. Nevertheless, these models may serve as invaluable tools to dissect contributions of various genetic changes (e.g., *ERG* overexpression, *TMPRSS2* loss, or haploinsufficiency of genes deleted between *TMPRSS2* and *ERG*) to the development of prostate cancer with gene fusions in human.

Specific aim 2: Explore roles of the ETS family transcription factor ERG in development and in normal prostate by making a conditional knockout allele of this gene in mouse.

As mentioned above, we generated an *Erg* knockdown allele (*Erg^{kd}*) in mice by placing a transcriptional stopper cassette into the *Erg* locus. Mice homozygous for this knockdown allele died before E11.5 during embryonic

development. At E10.5, homozygous embryos (*Erg*^{kd/kd}) appeared pale and there was only a trace amount of blood running in major vessels, suggesting a possible endothelial cell defect, or hematopoietic defect, or both (Figure 3). Since the stopper cassette we introduced is flanked by loxP site, Cre-mediated excision of this stopper cassette would allow us to restore *Erg* expression. We first restored *Erg* expression in both endothelial and blood cells during development by breeding with *Tie2-Cre* transgenic mice (24). This led to a complete rescue of the early lethality phenotype. We then restored *Erg* expression only in blood cells during development by breeding with the hematopoietic specific *Vav-Cre* transgenic mice. Surprisingly, this also led to rescue of the early lethal phenotype. These experiments suggest that during early development, *Erg* mainly plays a critical role in hematopoiesis, a finding similar to another recent study using a mutant loss-of-function allele for *Erg* generated from a forward genetic screen (25). Since both *Tie2-Cre* and *Vav-Cre* transgenes rescued the early lethal phenotype and would allow homozygous *Erg*^{kd/kd} mice to survive to adulthood, it would allow us to study the role of *Erg* in prostate development, since *Tie2-Cre* or *Vav-Cre* only restores *Erg* expression in endothelial and hematopoietic cells, not in prostate epithelial cells.

In addition, we are in the process of making an *Erg* conditional knockout allele by flanking its last coding exon with loxP sites. This last exon encodes the DNA binding domain of *Erg* that is critical for its function. For the first targeting vector we generated based on this design, we were not able to get any correctly targeted ES clones after screened several hundred clones, suggesting a genomic region (3' UTR) very difficult to target. We then modified this original targeting vector by extending its 3' homologous arm. After screening another several hundred ES clones, recently we obtained one clone that appeared correctly targeted at the 5' arm as determined by southern blot. Currently we are working on confirming this potential clone by testing its 3' arm by southern blot.

In summary, in this specific aim, we have not been able to create a conditional floxed *Erg* knockout allele as we initially designed, due to an unexpected technical difficulty (other people had described the same difficulty in generating such allele using a similar approach). However, we were able to use a conditionally rescuable *Erg* knockdown allele to study the role of *Erg* during early development. Rescued *Erg* knockdown mice would also allow us to study the role of *Erg* in adult tissues, especially in prostate.

Specific aim 3: Identify downstream target genes of ERG or ETV1 in human prostate cancer cell lines carrying these gene arrangements using the ChIP-on-Chip approach.

To identify new ERG and ETV1 target genes and collaborating factors in prostate development and disease, we used LNCaP and VCaP prostate cancer cell lines and RWPE immortalized normal prostate cell line (26). LNCaP cells overexpress ETV1 under the *HNRPA2B1* prostate-specific promoter (14), whereas VCaP cells are characterized by the presence of the TMPRSS2-ERG fusion protein (9). Both prostate cancer cell lines displayed high ERG (VCaP) and ETV1 (LNCaP) levels that increased after androgen stimulation.

Expressing profiling by microarrays has become a standard method to study cancer. To analyze further the role of ERG and ETV1 in the prostate, we have performed siRNA-silencing experiments. Eight and 48 hours after transient transfection with ERG and ETV1 specific siRNA from Dharmacon, LNCaP and VCaP cells were harvested. We hybridized total RNA prepared from androgen stimulated ERG and ETV1 siRNA silenced experiments onto Affymetrix human whole genome expression array U133Plus2.0 in the DFCI Gene Expression Core. From the recently obtained array data, we found ERG knockdown led to alterations in expression of genes for cell cycle & cell adhesion molecules, suggesting ectopic expression of ERG in prostate epithelial cells may alter their cell cycle status as well as their invasiveness.

Moreover, to identify potential target genes of ERG and ETV1 in prostate cancer, we planned to perform genome wide location analysis for mapping the *in vivo* ERG and ETV1 binding (or target) sites in normal and cancer cell lines. A key requirement for the success of this analysis is a reliable antibody that recognizes the protein of interest specifically in an immunoprecipitation assay. We tested several commercially available antibodies against human ERG and ETV1, and unfortunately they are not good for the process. Thus, to identify ERG and ETV1 binding sites, we utilized a metabolic biotin labeling approach (27, 28), in which the *ERG* and *ETV1* cDNA were engineered to contain an amino-terminal Flag epitope and a short peptide tag that serves as a substrate for *in vivo* biotinylation. This cDNA was then expressed in RWPE immortalized normal cells and in LNCaP, and VCaP cells (which were isolated from metastatic prostate cancer) previously engineered to ectopically express the *Escherichia coli* biotin ligase *BirA*. The exceptionally strong interaction between biotin and streptavidin allows for the efficient recovery of biotinylated protein with cross-linked DNA, as in conventional chromatin immunoprecipitation (ChIP) experiments. Recently, we generated LNCaP, VCaP and RWPE cells that contain

the *bioERG* and *bioETV1*, joined to biotin ligase BirA by retroviral infection. We also started the initial “bio-ChIP” experiment to test enrichment of several known ERG or ETV1 targets, as a proof of principle. In the near future, material recovered in this “bio-ChIP” method will be hybridized to Affymetrix promoter arrays to identify putative target genes of ERG or ETV1 globally. This approach (bio-ChIP-on-Chip) has been successfully utilized in our lab to identify target genes of pluripotency genes in embryonic stem cells (27, 28). By coupling ChIP-on-Chip information with the transcriptome analysis, we will identify candidate target genes of ERG and ETV1, which will be then validated by RT-PCR and ChIP assays. In addition, data comparing prostate normal and cancer cells will allow us to identify genetic/epigenetic changes involved in cancer initiation and progression.

Key research accomplishments:

- Successfully generated *Tmprss2-ERG* and *ETV1* knockin mice expressing truncated human ERG and ETV1 from the endogenous mouse *Tmprss2* locus.
- Successfully generated another mouse model for TMPRSS2-ERG fusion with both *Tmprss2* and *Erg* loci tagged by loxP sites.
- *In vivo* study suggests ectopic expression of ERG in mouse prostates alone is insufficient to initiate prostate cancer development.
- Generated a conditionally rescuable *Erg* knockdown allele in mice that would allow us to study roles of *Erg* during embryonic development and in prostate.
- Characterization of the above *Erg* knockdown allele suggests *Erg* plays a critical role in hematopoiesis during development.
- Analysis in prostate cancer cell lines suggests *Erg* knockdown led to alterations in expression of genes for cell cycle & cell adhesion molecules
- Generated Flag-tagged biotinylated ERG or ETV1 (*bioERG* and *bioETV1*) for biochemical studies.

Reportable outcomes:

2008 Presentation at the Dana Faber / Harvard Cancer Center Prostate SPORE program meeting: “Probing the mechanism of pathogenesis in prostate cancer with TMPRSS2-ERG gene rearrangement using preclinical mouse models”.

Animal models: *Tmprss2-ERG* knockin model, *Tmprss2-loxP-3Mb-loxP-Erg* sequential targeting model, *Erg* knockdown model.

Cell lines: LNCaP-BirA, LNCaP-BirA/bioETV1, RWPE-BirA, RWPE-BirA/bioERG, RWPE-BirA/bioETV1.

List of personnel (not salaries) receiving pay from the research effort: Esther Baena, PhD; Zhe Li, PhD.

Conclusion:

We planned to use both a series of mouse models and biochemical approaches to study the mechanisms of pathogenesis in human prostate cancer with *TMPPRSS2-ERG* (or *ETV1*) gene fusions. During the two-year award period, we have made significant progress, including successfully generating the conditional knockin mice carrying the *Tmprss2-ERG* (or *ETV1*) fusion allele, as well as those carrying the *Tmprss2-loxP-3Mb-loxP-Erg* allele through sequential targeting; establishing that ectopic expression of ERG alone in prostate is not sufficient

to initiate prostate cancer; generation and initial characterization of an *Erg* knockdown allele; establishing the critical role of *Erg* in blood cell development; establishing the role of ERG in controlling cell cycle and cell adhesion molecules; and establishment of a biotinylation system for both ERG and ETV1 in human prostate cancer cell lines for biochemical studies. Further studies using these animal and cell culture models would allow us to develop preclinical animal models, as well as to identify and validate novel therapeutic targets, for treating prostate cancer.

References:

1. D. S. Coffey, *Cancer* **71**, 880 (Feb 1, 1993).
2. S. Rizzo, G. Attard, D. L. Hudson, *Cell Prolif* **38**, 363 (Dec, 2005).
3. C. Abate-Shen, M. M. Shen, *Genes Dev* **14**, 2410 (Oct 1, 2000).
4. N. Cerveira *et al.*, *Neoplasia* **8**, 826 (Oct, 2006).
5. J. Clark *et al.*, *Oncogene* (Oct 16, 2006).
6. S. Perner *et al.*, *Cancer Res* **66**, 8337 (Sep 1, 2006).
7. M. J. Soller *et al.*, *Genes Chromosomes Cancer* (Mar 30, 2006).
8. S. A. Tomlins *et al.*, *Cancer Res* **66**, 3396 (Apr 1, 2006).
9. S. A. Tomlins *et al.*, *Science* **310**, 644 (Oct 28, 2005).
10. J. Wang, Y. Cai, C. Ren, M. Ittmann, *Cancer Res* **66**, 8347 (Sep 1, 2006).
11. M. Yoshimoto *et al.*, *Neoplasia* **8**, 465 (Jun, 2006).
12. R. Mehra *et al.*, *Mod Pathol* **20**, 538 (May, 2007).
13. B. E. Helgeson *et al.*, *Cancer Res* **68**, 73 (Jan 1, 2008).
14. S. A. Tomlins *et al.*, *Nature* **448**, 595 (Aug 2, 2007).
15. C. Kumar-Sinha, S. A. Tomlins, A. M. Chinnaiyan, *Nat Rev Cancer* **8**, 497 (Jul, 2008).
16. X. Wu *et al.*, *Mech Dev* **101**, 61 (Mar, 2001).
17. O. Klezovitch *et al.*, *Proc Natl Acad Sci U S A* **105**, 2105 (Feb 12, 2008).
18. S. A. Tomlins *et al.*, *Neoplasia* **10**, 177 (Feb, 2008).
19. S. Wilson *et al.*, *Biochem J* **388**, 967 (Jun 15, 2005).
20. J. M. Lucas *et al.*, *J Pathol* **215**, 118 (Jun, 2008).
21. M. H. Vaarala, K. Porvari, A. Kyllonen, O. Lukkarinen, P. Vihko, *Int J Cancer* **94**, 705 (Dec 1, 2001).
22. R. Mehra *et al.*, *Cancer Res* **68**, 3584 (May 15, 2008).
23. S. Wang *et al.*, *Cancer Cell* **4**, 209 (Sep, 2003).
24. Y. Y. Kisanuki *et al.*, *Dev Biol* **230**, 230 (Feb 15, 2001).
25. S. J. Loughran *et al.*, *Nat Immunol* **9**, 810 (Jul, 2008).
26. D. Bello, M. M. Webber, H. K. Kleinman, D. D. Wartinger, J. S. Rhim, *Carcinogenesis* **18**, 1215 (Jun, 1997).
27. J. Kim, J. Chu, X. Shen, J. Wang, S. H. Orkin, *Cell* **132**, 1049 (Mar 21, 2008).
28. J. Wang *et al.*, *Nature* **444**, 364 (Nov 16, 2006).

Appendices:

None

Supporting Data:




Figure 1. Expression of the *Tmprss2*-*ERG* fusion transcript from the Stopper-excised *Tmprss2*-*ERG* knockin allele (thus activated) determined by RT-PCR. PCR primers used to detect the endogenous *Tmprss2* transcript and the *Tmprss2*-*ERG* fusion transcript are shown in the schematic drawing (red arrows). PCR primers used to detect the endogenous mouse *Erg* are located in exons further downstream (not shown).

Mouse chromosome 16:




Figure 2. The upper panel shows the schematic diagram of the *Erg* and *Tmprss2* loci tagged by loxP sites on the same mouse chromosome 16 (*Tmprss2-loxP-3Mb-loxP-Erg*). Cre-mediated recombination deletes the ~3Mb region between the first loxP site at the *Tmprss2* locus and the single loxP at the *Erg* locus. Forward and reverse primers designed to amplify the region surrounding the single remaining loxP site after excision are indicated by red arrows. The lower left panel shows PCR results using these two primers for three ES clones (#74, 84, 87) from sequential targeting, after transient transfection with a Cre-expressing plasmid. T: control DNA without Cre. The lower right panel shows the sequencing result for the PCR band showed on the left panel confirming correct recombination between the *Tmprss2* and *Erg* loci.




Figure 3. *Erg* knockdown allele. Mouse embryos homozygous for this *Erg* knockdown (kd) allele die before E11.5, possibly due to a hematopoietic defect, or vascular defect, or both. Dramatic reduction of *Erg* expression was detected by RT-PCR in hematopoietic cells derived from E9.5 yolk sac progenitors. *Erg* expression can be restored by Cre-mediated excision of the Neo-Stopper (ST) cassette.